{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108280","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.707937+00:00","generated_at":"2026-05-17T13:48:29.968254+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"FibroGen amends debt agreement, reduces minimum cash requirement from $18.75M to $15M","bullets":["Fourth Amendment to Financing Agreement with Morgan Stanley Tactical Value lenders executed August 12, 2025.","Minimum qualified cash balance reduced from $18.75 million to $15.0 million effective immediately.","Prior amendments dated May 8, June 5, and July 14, 2025 indicate ongoing covenant adjustments."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108280","json":"https://secwatch.observer/filing/0000950170-25-108280.json","markdown":"https://secwatch.observer/filing/0000950170-25-108280.md","text":"https://secwatch.observer/filing/0000950170-25-108280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017025108280/0000950170-25-108280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017025108280/fgen-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:48:29.968254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}